Telmisartan is a long-acting blood-pressure medication that also gently supports how the body handles sugar and fat. It reliably lowers blood pressure and, in high-risk people, helps prevent heart attacks and strokes. It modestly improves insulin sensitivity, inflammation, blood-vessel flexibility, and kidney protection. Its longevity promise remains a reasonable hypothesis, not a proven effect. (Full Review)

Protocol

Standard Dose

40 mg once daily

Titrate to 80 mg after 2–4 weeks if targets unmet; 20 mg reserved for frail or volume-depleted.

Timing

Any consistent time

Single daily dose; some favor evening for overnight coverage. Long half-life makes timing less critical.

Older Adults

Start 20–40 mg

Slower titration due to greater sensitivity to blood-pressure lowering and higher fall risk.

Time to effect

Blood Pressure Onset

Within days

Blood-pressure lowering begins within the first days.

Full BP Effect

4–8 weeks

Full antihypertensive effect typically reached by 4–8 weeks.

Metabolic & Inflammatory

Weeks to months

Metabolic and inflammatory changes, where they occur, unfold over weeks to months.

Benefits

High: Blood pressure reduction; cardiovascular event prevention in high-risk individuals

Medium: Improved insulin sensitivity; anti-inflammatory effects; improved endothelial function; kidney protection

Low: Favorable fat distribution

Speculative: Neuroprotection and cognitive preservation; anti-cancer potential; longevity and healthspan extension

Contraindications

Pregnancy (absolute, boxed warning)

History of angioedema on RAAS therapy

Bilateral renal artery stenosis

Severe hepatic impairment (Child-Pugh Class C)

Biliary obstruction

Key Interactions

Other RAAS inhibitors (ACE inhibitors: ramipril, lisinopril; aliskiren)

Potassium-sparing diuretics and potassium supplements (spironolactone, eplerenone, amiloride, triamterene)

NSAIDs (ibuprofen, naproxen)

Lithium

Digoxin

Other blood-pressure-lowering agents and supplements (diuretics, calcium channel blockers, beta-blockers; potassium, magnesium, hibiscus, garlic extract, beetroot/nitrate, CoQ10)

Risk & Side Effects

High: Hypotension and dizziness; hyperkalemia; kidney function decline in susceptible individuals

Medium: Fetal toxicity

Low: Back pain and musculoskeletal symptoms; upper respiratory and sinus symptoms

Speculative: Angioedema; long-term effects of preventive use in healthy individuals

Monitoring

Marker	Target	Why
Blood pressure	~110–125 / 70–80 mmHg	Primary efficacy target
Serum potassium	4.0–4.8 mmol/L	Detects hyperkalemia risk
eGFR	>90 mL/min/1.73m²	Tracks kidney filtration
Serum creatinine	0.6–1.0 mg/dL	Confirms kidney function
Urine albumin-to-creatinine ratio	<10 mg/g	Kidney-protection marker
Fasting glucose	75–90 mg/dL	Metabolic response
Fasting insulin	2–6 µU/mL	Insulin-sensitivity response
hs-CRP	<1.0 mg/L	Inflammation marker

Cadence: Check blood pressure, potassium, and eGFR at 1–2 weeks and 4 weeks after starting or any dose change, then every 3–6 months once stable, and at least annually thereafter; metabolic and inflammatory markers every 6–12 months.

Qualitative Assessment

Absence of dizziness, lightheadedness, or fainting on standing
Stable energy levels without new fatigue
No new facial or airway swelling (angioedema warning sign)
Consistent home blood-pressure readings within target
No new muscle or back discomfort attributable to the drug

Telmisartan for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment